The most recent ESAIC guidelines recommend to hold GLP-1 agonists at least one week, prior to scheduling procedures that require sedation or anaesthesia for patients who inject weekly.11 Furthermore, the guidelines specify that if the medications are given for obesity, then two weeks (i.e, three half-lives) are recommended. This evidence concerns the gene GLP1R and obesity disorder.